search
Back to results

Optimizing Psychological Treatment for Pain After Breast Cancer: A Pilot Study

Primary Purpose

Pain, Chronic, Breast Cancer

Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Mindful attention
Decentering
Value-based action
Sponsored by
University of Aarhus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain, Chronic focused on measuring Breast cancer, Pain, Third wave cognitive therapy, Mindful attention, Decentering, Values and committed action, The Multiphase Optimization Strategy (MOST), Psychological pain treatment, Treatment mediators

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion criteria:

  • Diagnosis of primary breast cancer stage I-III
  • Min. 6 months post breast cancer treatment (i.e., surgery, chemotherapy, and/or radiotherapy). Endocrine treatment, e.g., Letrozole or Tamoxifen, and/or Zoledronic acid and/or Herceptin treatment is allowed during study participation
  • Pain corresponding to a min. pain score of >= 3 on pain intensity or pain interference measured by 11-point Numeric Rating Scales (NRSs)
  • Sufficient ability to communicate in Danish
  • Sufficient ability to participate in an online-delivered intervention

Exclusion Criteria:

  • Metastatic breast cancer (stage IV)
  • Breast cancer recurrence
  • Bilateral breast cancer
  • Other current cancer disease
  • Other current pain condition (e.g., fibromyalgia)
  • Current severe psychiatric disorder (e.g., psychosis)
  • Inability to communicate in Danish
  • Inability to participate in an online-delivered intervention

Sites / Locations

  • Aarhus University

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm Type

No Intervention

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Waitlist control

Mindful attention

Decentering

Values and committed action

Mindful attention + Decentering

Mindful attention + Values and committed action

Decentering + Values and committed action

Mindful attention + Decentering + Value-based action

Arm Description

Participants randomized to condition 1 are not offered any treatment components immediately upon enrollment, but will be offered a treatment component of own choice at the end of the study. Total number of sessions: 2 (2 contact hours) following study completion.

Participants randomized to condition 2 will receive the Mindful attention treatment component. Total number of sessions: 2 (2 contact hours).

Participants randomized to condition 3 will receive the Decentering treatment component. Total number of sessions: 2 (2 contact hours).

Participants randomized to condition 4 will receive the Values and committed action treatment component. Total number of sessions: 2 (2 contact hours).

Participants randomized to condition 5 will receive the Mindful attention treatment component and the Decentering treatment component. Total number of sessions: 4 (4 contact hours).

Participants randomized to condition 6 will receive the Mindful attention treatment component and the Values and committed action treatment component. Total number of sessions: 4 (4 contact hours).

Participants randomized to condition 7 will receive the Decentering treatment component and the Values and committed action treatment component. Total number of sessions: 4 (4 contact hours).

Participants randomized to condition 8 will receive the Mindful attention treatment component, the Decentering treatment component, and the Values and committed action treatment component. Total number of sessions: 6 (6 contact hours).

Outcomes

Primary Outcome Measures

Pain intensity (11-point Numeric Rating Scale, NRS)
The NRS is a validated, self-report instrument assessing pain intensity during the last week. Answer format range: 0 (no pain) to 10 (worst possible pain); total score range: 0-10. Higher scores yield more pain.
Pain interference (the 7-item subscale of the Brief Pain Inventory, BPI)
The BPI is a validated, self-report instrument assessing clinical pain. The BPI pain interference subscale assesses pain interference during the last week across 7 domains, i.e., general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Answer format range: 0 (no interference) to 10 (maximal interference); total score range: 0-10. Higher scores yield more pain interference.

Secondary Outcome Measures

Pain intensity (11-point Numeric Rating Scale, NRS)
Pain intensity during the last 24 hours will be assessed every day for 6 days following the first session (Td) for each treatment component using the NRS. Answer format range: 0 (no pain) to 10 (worst possible pain); total score range: 0-10. Higher scores yield more pain.
4. Pain interference (1 aggregated item assessing pain interference during the last 24 hours within the 7 domains measured with the Brief Pain Inventory, BPI, interference subscale)
Pain interference during the last 24 hours will be assessed every day for 6 days following the first session (Td) for each treatment component using 1 aggregated item assessing pain interference across the 7 domains measured with the BPI interference subscale, i.e., general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Answer format range: 0 (no interference) to 10 (maximal interference); total score range: 0-10. Higher scores yield more pain interference.
Pain burden (11-point Numeric Rating Scale, NRS)
The NRS is a validated, self-report instrument assessing pain burden during the last week. Answer format range: 0 (no burden) to 10 (maximal burden); total score range: 0-10. Higher scores yield more pain burden.
Pain quality (the 22-item pain descriptors from the McGill Pain Questionnaire, MPQ)
The pain descriptors from the MPQ constitutes a validated, self-report instrument assessing pain quality (i.e., pain type, namely continuous pain, intermittent pain, neuropathic pain, affective pain) during the last week. Answer format range: 0 (no pain) to 10 (worst possible pain); total score range: 0-60 (continuous, neuropathic and intermittent pain), 0-40 (affective pain). Higher scores yield more pain.
Pain catastrophizing (the 13-item Pain Catastrophizing Scale, PCS)
The PCS is a validated, self-report instrument assessing pain catastrophizing. Answer format range: 0 (not at all) to 4 (all the time); total score range: 0-52. Higher scores yield more pain catastrophizing.
Psychological distress (the 14-item Hospital Anxiety and Depression Scale, HADS)
The HADS is a validated, self-report instrument assessing psychological distress during the last week. Answer format range: 0 (not at all or never) to 3 (most or all of the time); total score range 0-42. Higher scores yield more distress.
Fear of cancer recurrence (the 9-item Fear of Cancer Recurrence Inventory, FCRI)
The FCRI is a validated, self-report instrument assessing fear of cancer recurrence during the last month. Answer format range: 0 (not at all) to 4 (a great deal); total score range 0-36. Higher scores yield more fear of cancer recurrence.
Well-being (the 5-item WHO-5 Well-Being Index, WHO-5)
The WHO-5 is a validated, self-report instrument assessing current well-being. Answer format range: 0 (at no time) to 5 (all the time); total score range: 0-100. Higher scores yield more well-being.

Full Information

First Posted
March 23, 2021
Last Updated
September 29, 2021
Sponsor
University of Aarhus
Collaborators
Danish Council for Independent Research
search

1. Study Identification

Unique Protocol Identification Number
NCT04841928
Brief Title
Optimizing Psychological Treatment for Pain After Breast Cancer: A Pilot Study
Official Title
Optimization of Psychological Treatment for Pain After Breast Cancer Using the Multiphase Optimization Strategy (MOST): A Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Completed
Study Start Date
March 1, 2021 (Actual)
Primary Completion Date
July 1, 2021 (Actual)
Study Completion Date
August 1, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Aarhus
Collaborators
Danish Council for Independent Research

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The present study is a pilot study that aims to evaluate the feasibility, validity, and preliminary efficacy of three psychological treatment components for pain after breast cancer, which will be evaluated in a larger trial following completion of the present pilot study.
Detailed Description
The present pilot study is a precursor for a following larger trial and aims to evaluate the i) feasibility, ii) validity, and iii) preliminary efficacy of the three treatment components that will be further investigated in a subsequent larger trial. The present pilot study will employ the same design as will be used in the subsequent larger trial, namely the Multiphase Optimization Strategy (MOST). Specifically, in the subsequent larger trial, MOST will be used to evaluate the efficacy and change processes of three psychological treatment components selected from so-called "third wave" cognitive therapies (CTs), which have been shown to be efficacious in the treatment of pain after breast cancer. The overall hypothesis is that the selected third wave CT components will target key maintaining psychological factors in pain, thus leading to reductions in the primary outcomes of pain intensity and -interference. Specifically, we hypothesize that: Mindful attention practices will increase attentional control (i.e., the ability to intentionally focus and intentionally shift one's attention), thereby reducing pain hypervigilance, leading to reductions in pain intensity and -interference. Decentering practices will reduce fusion with thoughts (i.e., getting caught up in one's thoughts and acting automatically in response to thoughts), thereby reducing pain catastrophizing, leading to reductions in pain intensity and -interference. Values and committed action (i.e., behavior linked to values and goals) will increase acceptance of discomfort and reduce avoidant behavior, leading to reductions in pain intensity and -interference.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Chronic, Breast Cancer
Keywords
Breast cancer, Pain, Third wave cognitive therapy, Mindful attention, Decentering, Values and committed action, The Multiphase Optimization Strategy (MOST), Psychological pain treatment, Treatment mediators

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Model Description
The study uses a 2^3 factorial design, randomizing participants to 8 experimental conditions
Masking
None (Open Label)
Allocation
Randomized
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Waitlist control
Arm Type
No Intervention
Arm Description
Participants randomized to condition 1 are not offered any treatment components immediately upon enrollment, but will be offered a treatment component of own choice at the end of the study. Total number of sessions: 2 (2 contact hours) following study completion.
Arm Title
Mindful attention
Arm Type
Experimental
Arm Description
Participants randomized to condition 2 will receive the Mindful attention treatment component. Total number of sessions: 2 (2 contact hours).
Arm Title
Decentering
Arm Type
Experimental
Arm Description
Participants randomized to condition 3 will receive the Decentering treatment component. Total number of sessions: 2 (2 contact hours).
Arm Title
Values and committed action
Arm Type
Experimental
Arm Description
Participants randomized to condition 4 will receive the Values and committed action treatment component. Total number of sessions: 2 (2 contact hours).
Arm Title
Mindful attention + Decentering
Arm Type
Experimental
Arm Description
Participants randomized to condition 5 will receive the Mindful attention treatment component and the Decentering treatment component. Total number of sessions: 4 (4 contact hours).
Arm Title
Mindful attention + Values and committed action
Arm Type
Experimental
Arm Description
Participants randomized to condition 6 will receive the Mindful attention treatment component and the Values and committed action treatment component. Total number of sessions: 4 (4 contact hours).
Arm Title
Decentering + Values and committed action
Arm Type
Experimental
Arm Description
Participants randomized to condition 7 will receive the Decentering treatment component and the Values and committed action treatment component. Total number of sessions: 4 (4 contact hours).
Arm Title
Mindful attention + Decentering + Value-based action
Arm Type
Experimental
Arm Description
Participants randomized to condition 8 will receive the Mindful attention treatment component, the Decentering treatment component, and the Values and committed action treatment component. Total number of sessions: 6 (6 contact hours).
Intervention Type
Behavioral
Intervention Name(s)
Mindful attention
Intervention Description
The Mindful attention treatment component consists of a breathing exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
Intervention Type
Behavioral
Intervention Name(s)
Decentering
Intervention Description
The Decentering treatment component consists of a guided imagery exercise and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
Intervention Type
Behavioral
Intervention Name(s)
Value-based action
Intervention Description
The Values and committed action treatment component consists of identification of personal values and committed action, and is operationalized as two sessions (1 hour each) delivered over two weeks, i.e., one session per week, with homework between sessions. Sessions will be delivered online.
Primary Outcome Measure Information:
Title
Pain intensity (11-point Numeric Rating Scale, NRS)
Description
The NRS is a validated, self-report instrument assessing pain intensity during the last week. Answer format range: 0 (no pain) to 10 (worst possible pain); total score range: 0-10. Higher scores yield more pain.
Time Frame
Baseline (T1) to 1 week after last session (Post-intervention, T2)
Title
Pain interference (the 7-item subscale of the Brief Pain Inventory, BPI)
Description
The BPI is a validated, self-report instrument assessing clinical pain. The BPI pain interference subscale assesses pain interference during the last week across 7 domains, i.e., general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Answer format range: 0 (no interference) to 10 (maximal interference); total score range: 0-10. Higher scores yield more pain interference.
Time Frame
Baseline (T1) to 1 week after last session (Post-intervention, T2)
Secondary Outcome Measure Information:
Title
Pain intensity (11-point Numeric Rating Scale, NRS)
Description
Pain intensity during the last 24 hours will be assessed every day for 6 days following the first session (Td) for each treatment component using the NRS. Answer format range: 0 (no pain) to 10 (worst possible pain); total score range: 0-10. Higher scores yield more pain.
Time Frame
Every day for 6 days following the first session (Td) for each treatment component
Title
4. Pain interference (1 aggregated item assessing pain interference during the last 24 hours within the 7 domains measured with the Brief Pain Inventory, BPI, interference subscale)
Description
Pain interference during the last 24 hours will be assessed every day for 6 days following the first session (Td) for each treatment component using 1 aggregated item assessing pain interference across the 7 domains measured with the BPI interference subscale, i.e., general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Answer format range: 0 (no interference) to 10 (maximal interference); total score range: 0-10. Higher scores yield more pain interference.
Time Frame
Every day for 6 days following the first session (Td) for each treatment component
Title
Pain burden (11-point Numeric Rating Scale, NRS)
Description
The NRS is a validated, self-report instrument assessing pain burden during the last week. Answer format range: 0 (no burden) to 10 (maximal burden); total score range: 0-10. Higher scores yield more pain burden.
Time Frame
Baseline (T1) to 1 week after last session (Post-intervention, T2)
Title
Pain quality (the 22-item pain descriptors from the McGill Pain Questionnaire, MPQ)
Description
The pain descriptors from the MPQ constitutes a validated, self-report instrument assessing pain quality (i.e., pain type, namely continuous pain, intermittent pain, neuropathic pain, affective pain) during the last week. Answer format range: 0 (no pain) to 10 (worst possible pain); total score range: 0-60 (continuous, neuropathic and intermittent pain), 0-40 (affective pain). Higher scores yield more pain.
Time Frame
Baseline (T1) to 1 week after last session (Post-intervention, T2)
Title
Pain catastrophizing (the 13-item Pain Catastrophizing Scale, PCS)
Description
The PCS is a validated, self-report instrument assessing pain catastrophizing. Answer format range: 0 (not at all) to 4 (all the time); total score range: 0-52. Higher scores yield more pain catastrophizing.
Time Frame
Baseline (T1) to 1 week after last session (Post-intervention, T2)
Title
Psychological distress (the 14-item Hospital Anxiety and Depression Scale, HADS)
Description
The HADS is a validated, self-report instrument assessing psychological distress during the last week. Answer format range: 0 (not at all or never) to 3 (most or all of the time); total score range 0-42. Higher scores yield more distress.
Time Frame
Baseline (T1) to 1 week after last session (Post-intervention, T2)
Title
Fear of cancer recurrence (the 9-item Fear of Cancer Recurrence Inventory, FCRI)
Description
The FCRI is a validated, self-report instrument assessing fear of cancer recurrence during the last month. Answer format range: 0 (not at all) to 4 (a great deal); total score range 0-36. Higher scores yield more fear of cancer recurrence.
Time Frame
Baseline (T1) to 1 week after last session (Post-intervention, T2)
Title
Well-being (the 5-item WHO-5 Well-Being Index, WHO-5)
Description
The WHO-5 is a validated, self-report instrument assessing current well-being. Answer format range: 0 (at no time) to 5 (all the time); total score range: 0-100. Higher scores yield more well-being.
Time Frame
Baseline (T1) to 1 week after last session (Post-intervention, T2)
Other Pre-specified Outcome Measures:
Title
Qualitative Interviews
Description
Participants will be invited to participate in a 30-minutes semi-structured individual interview 10-14 days after their last session. The interview serves to support the validation of the treatment components and to provide in-depth knowledge about the participants' experiences through their qualitative comments.
Time Frame
10-14 days after last session
Title
Moderator: Demographic characteristics
Description
Socio-demographic characteristics will be assessed using single questions (e.g., municipality, marital status, income, work status).
Time Frame
Baseline (T1)
Title
Moderator: Clinical characteristics
Description
Clinical characteristics will be assessed using single questions (e.g., date of surgery, adjuvant therapy).
Time Frame
Baseline (T1)
Title
Moderator: Treatment expectancy
Description
Treatment expectancy will be assessed using a single question regarding the extent to which the participant believes that the intervention will reduce pain and increase overall well-being. Answer format range: 1 (not at all) to 5 (a great deal); total score range: 1-5. Higher scores indicate stronger expectations that the intervention will lead to a positive outcome.
Time Frame
Baseline (T1)
Title
Moderator: Therapeutic alliance (the 12-item Working Alliance Inventory, WAI) Revised Short Form
Description
The WAI is a validated, self-report instrument assessing therapeutic alliance. Answer format range: 1 (never) to 7 (all the time); total score range: 12-84. Higher scores yield a stronger therapeutic alliance.
Time Frame
1 week after last session (Post-intervention, T2)
Title
Moderator: Home work
Description
Homework will be assessed with 4 single items related to i) whether home work has been conducted (yes/no), and the ii) type, iii) frequency (number of days per week), and iv) duration of completed homework (average number of minutes per day).
Time Frame
Before each session (Ts) and 1 week after last session (Post-intervention, T2)
Title
Mediator: Mindful attention (the 15-item Mindful Attention Awareness Scale, MAAS)
Description
The MAAS is a validated, self-report instrument assessing individual differences in the frequency of mindful states over time. Answer format range: 1 (almost always) to 6 (almost never); total score range: 1-6. Higher scores yield higher levels of mindful attention.
Time Frame
Baseline (T1) to 1 week after last session (Post-intervention, T2)
Title
Mediator: Mindful attention (2 items from the 15-item Mindful Attention Awareness Scale, MAAS)
Description
MAAS items 13 and 7 will be assessed before each session (Ts). Answer format range: 1 (almost always) to 6 (almost never). Higher scores yield higher levels of mindful attention.
Time Frame
Before each session (Ts)
Title
Mediator: Mindful attention (1 item from the 15-item Mindful Attention Awareness Scale, MAAS)
Description
MAAS item 6 will be assessed every day for 6 days following the first session (Td) for each treatment component. Answer format range: 1 (almost always) to 6 (almost never). Higher scores yield higher levels of mindful attention.
Time Frame
Every day for 6 days following the first session for each treatment component (Td)
Title
Mediator: Decentering (the 11-item subscale of the Experiences Questionnaire, EQ)
Description
The EQ is a validated, self-report instrument assessing decentering. Answer format range: 1 (do not agree at all) to 5 (agree completely); total score range: 11-55. Higher scores yield higher levels of decentering.
Time Frame
Baseline (T1) to 1 week after last session (Post-intervention, T2)
Title
Mediator: Decentering (2 items from the 11-item subscale of the Experiences Questionnaire, EQ)
Description
EQ items 5 and 7 will be assessed before each session (Ts). Answer format range: 1 (do not agree at all) to 5 (agree completely). Higher scores yield higher levels of decentering.
Time Frame
Before each session (Ts)
Title
Mediator: Decentering (1 item from the 11-item subscale of the Experiences Questionnaire, EQ)
Description
EQ item 5 will be assessed every day for 6 days following the first session (Td) for each treatment component. Answer format range: 1 (do not agree at all) to 5 (agree completely). Higher scores yield higher levels of decentering.
Time Frame
Every day for 6 days following the first session for each treatment component (Td)
Title
Mediator: Pain acceptance and activity engagement (the 20-item Chronic Pain Acceptance Scale, CPAS)
Description
The CPAS is a validated, self-report instrument assessing pain acceptance and activity engagement. Answer format range: 0 (never true) to 6 (always true); subscale score range: 0-54 (pain acceptance subscale), 0-66 (activity engagement subscale). Higher scores yield more acceptance and activity engagement.
Time Frame
Baseline (T1) to 1 week after last session (Post-intervention, T2)
Title
Mediator: Pain acceptance and activity engagement (2 items from the 20-item Chronic Pain Acceptance Scale, CPAS)
Description
CPAS items 1 and 12 will be assessed before each session (Ts). Answer format range: 0 (never true) to 6 (always true). Higher scores yield more acceptance and activity engagement.
Time Frame
Before each session (Ts)
Title
Mediator: Pain acceptance and activity engagement (1 item from the 20-item Chronic Pain Acceptance Scale, CPAS)
Description
CPAS item 1 will be assessed every day for 6 days following the first session (Td) for each treatment component. Answer format range: 0 (never true) to 6 (always true). Higher scores yield more acceptance and activity engagement.
Time Frame
Every day for 6 days following the first session for each treatment component (Td)

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Diagnosis of primary breast cancer stage I-III Min. 6 months post breast cancer treatment (i.e., surgery, chemotherapy, and/or radiotherapy). Endocrine treatment, e.g., Letrozole or Tamoxifen, and/or Zoledronic acid and/or Herceptin treatment is allowed during study participation Pain corresponding to a min. pain score of >= 3 on pain intensity or pain interference measured by 11-point Numeric Rating Scales (NRSs) Sufficient ability to communicate in Danish Sufficient ability to participate in an online-delivered intervention Exclusion Criteria: Metastatic breast cancer (stage IV) Breast cancer recurrence Bilateral breast cancer Other current cancer disease Other current pain condition (e.g., fibromyalgia) Current severe psychiatric disorder (e.g., psychosis) Inability to communicate in Danish Inability to participate in an online-delivered intervention
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maja Johannsen, PhD
Organizational Affiliation
University of Aarhus
Official's Role
Principal Investigator
Facility Information:
Facility Name
Aarhus University
City
Aarhus
State/Province
Central Denmark Region
ZIP/Postal Code
8000
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Optimizing Psychological Treatment for Pain After Breast Cancer: A Pilot Study

We'll reach out to this number within 24 hrs